VIPR1 and Arthritis: In addition, treatment with a VPAC1 agonist decreased the inflammatory response during progression of collagen-induced arthritis by down-regulating the production of various inflammatory mediators and reduced the presence of autoreactive Th1 cells in the joints [21].